Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure extending the disclosure postponement period and the contract period disclosure timeline to December 31, 2026, at the customer’s request regarding the contract manufacturing agreement with Sun Pharma Global FZE originally disclosed on July 4, 2017.
📊 [Key Disclosure Details & Financial Figures]
- Original Filing & Submission Date: Single Sales and Supply Contract (Submitted on July 4, 2017)
- Reason for Correction: Extension of disclosure postponement period at the customer’s request
- Key Correction Items:
- Disclosure Postponement Period: (Before) December 31, 2025 → (After) December 31, 2026
- Other Important Matters (Contract Period Disclosure Timeline): (Before) To be disclosed after December 31, 2025 → (After) To be disclosed after December 31, 2026
- Contract Overview (Based on Original Filing):
- Contract Title: Pharmaceutical Contract Manufacturing Agreement
- Contract Amount: KRW 63,563,203,675 (USD 55,513,715 / Based on minimum purchase quantities, applied exchange rate KRW 1,145.00 per USD)
- Recent Annual Revenue: KRW 294,622,020,774 (Based on FY2016 financial statements)
- Contract Amount to Revenue Ratio: 21.57%
- Counterparty: Sun Pharma Global FZE
- Contract Period Start Date: July 4, 2017
- Contract Date: July 4, 2017
- Other Important Investment Details:
- The contract amount may increase upon mutual agreement with the counterparty.
- The contract period is slated for disclosure after December 31, 2026, due to business confidentiality.
- The contract end date and contract amount are subject to change upon mutual agreement.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Disclosure Timeline and Contract Updates Following Postponement Extension
This correction disclosure extends the confidentiality postponement period and contract period disclosure timeline for the contract manufacturing deal with Sun Pharma Global FZE to December 31, 2026.
Monitoring the adjusted disclosure schedule and potential updates to unstated contract details or contract amounts is crucial for tracking the ongoing execution of this agreement.
Relevant developments can be verified upon the expiration of the extended postponement period (December 31, 2026) or through subsequent correction disclosures and periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
